Paragon Labs Recruited Apogee Therapeutics Leadership Team
The Boston-based incubator has tapped former Apogee executives to accelerate its drug discovery and spinout strategy.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that shifting leadership between related biotech companies serves the best interest of patients?
Paragon Labs has appointed former Apogee Therapeutics CEO Michael Henderson and several key executives to lead its biotech incubator operations. This leadership shuffle follows the $10.9 billion acquisition of Apogee Therapeutics by AbbVie.
Why it matters
Paragon Labs intends to apply the clinical and regulatory frameworks developed at Apogee to its ongoing portfolio. The firm aims to replicate the success of its previous spinouts as it prepares its current drug programs for long-term development.
A $350 million private placement, led by Fairmount, will fund the combined Alaunos and Velaris entity. This capital is projected to support operations and research activities through 2029.
The players
Michael Henderson
The new CEO of Paragon Labs and former head of Apogee Therapeutics.
AbbVie
A global biopharmaceutical company that acquired Apogee Therapeutics for $10.9 billion.
Alaunos Therapeutics
A biotech firm that acquired the Paragon spinout Velaris Therapeutics.
Fairmount
The investment firm that founded Paragon Labs in 2021 and led the $350 million private placement.
The details
Paragon Labs utilizes an incubator model designed to spin out specialized biotech firms to advance specific drug discovery programs. The company previously founded Apogee Therapeutics to develop zumilokibart, an antibody-based treatment. The newly integrated team at Paragon will oversee the development of Velaris Therapeutics, which focuses on a pipeline of ligand traps—proteins engineered to bind and sequester signaling molecules—to treat pulmonary hypertension.
Timeline
Fairmount founded Paragon Labs in 2021.
AbbVie announced its $10.9 billion acquisition of Apogee Therapeutics in June 2026.
Paragon Labs announced the new leadership appointments on October 13, 2026.
The $350 million in private placement funding is expected to support the company through 2029.
The Tech Race
The move follows the $10.9 billion acquisition of Apogee Therapeutics by AbbVie, establishing a high benchmark for the incubator's future spinouts. Paragon is now scaling its operations to compete in the specialized ligand trap market, directly targeting the development of treatments for pulmonary hypertension.
The transition secures long-term runway for the combined company through 2029, ensuring stability for its clinical programs. Researchers and stakeholders in the Boston life sciences cluster should monitor the progress of the Velaris Therapeutics pipeline as it nears clinical milestones.
The takeaway
Paragon Labs is banking on its ability to recycle executive expertise to navigate high-stakes drug development. Watch for the first clinical data readouts from the Velaris ligand trap program, which will serve as the primary proof of concept for this new leadership team.
Further reading
For more on the latest research and organizational shifts in the region, visit Biotech.
Live Poll
Do you trust that shifting leadership between related biotech companies serves the best interest of patients?
